April 14, 2015By Mark Terry, BioSpace.com Breaking News Staff Bayer HealthCare, a division of Germany-based Bayer AG (BAYZF), announced today that it will spend $100 million to expand its facilities near its campus in East Bay San Francisco. The new building will be 80,000-square-feet in size and will replace an older facility. The new build […]

(Reuters Health) – Losing weight in middle age may mean losing not just unwanted fat, but also precious bone density, at least for women, a new U.S. study suggests.   Regardless of the types of foods or amount of calcium in their diets, middle aged women who lost a moderate amount of weight over a […]

Mechanism Outlined By Which Inadequate Vitamin E Can Cause Brain Damage CORVALLIS, Ore. – Researchers at Oregon State University have discovered how vitamin E deficiency may cause neurological damage by interrupting a supply line of specific nutrients and robbing the brain of the “building blocks” it needs to maintain neuronal health. The findings – in […]

– First evidence of treatment-related remyelination in the human central nervous system –   – Ongoing SYNERGY trial will further inform potential for anti-LINGO-1 in MS –   CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today, Biogen (NASDAQ: BIIB) announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis (AON) – the first clinical study […]

BALTIMORE, Apr. 15, 2015 /PRNewswire/ –Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new research update on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and […]

(Reuters) – Having seen off a hostile $118 billion bid launched a year ago by U.S. rival Pfizer, Anglo-Swedish company AstraZeneca is on the move — quite literally.  As of last month, a four-days-a-week service set up by the drugmaker with Sun Air is connecting staff in its new Cambridge science and operations hub with […]

ALISO VIEJO, Calif., April 15, 2015 /PRNewswire/ — Avanir Pharmaceuticals, Inc. today announced that data highlighting its central nervous system (CNS) therapeutics franchise, including data from the Phase 2 study of AVP-923 for the treatment of agitation in Alzheimer’s disease, data from the Alzheimer’s cohort of PRISM II of NUEDEXTA® for the treatment of Pseudobulbar […]

CRANBURY, N.J., April 15, 2015 /PRNewswire/ — Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing biosimilars, today announced that clinical development for ONS-1045, an Avastin®/bevacizumab biosimilar candidate, is underway with dosing completed in its pivotal pharmacokinetic (PK) study.  This study is currently being conducted at the Center for Human Drug Research (CHDR) in Leiden, […]

Traumatic events during childhood may increase kids’ risk of developing type 1 diabetes, a Swedish study suggests. The researchers questioned more than 10,000 families and found that children who experienced an extremely stressful life event – like divorce, illness or death in the family – were about three times more likely to develop type 1 […]

The Pfizer logo is seen at their world headquarters in New York April 28, 2014. Reuters/Andrew Kelly Pfizer Inc said on Wednesday the first formal late-stage trial of its approved treatment for advanced breast cancer, Ibrance, was stopped early after the medicine met its goal of delaying progression of the disease in previously treated patients. […]